Date	18/12/2025

Parte A. PERSONAL INFORMATION

First Name	José Ángel		
Last Name	Morales García		
Gender		Date of birth	
National ID Number		Phone	
URL Web			
Email Address			
Researcher ID	Open Researcher and Contributor ID (ORCID)		
	Researcher ID		
	Scopus Author ID		

A.1. Current Professional Status

Position / Job Title	Tenured Professor	
Start Date		
Organization / Agency	Universidad Complutense de Madrid (UCM)	
Department / Center	Cell Biology and Histology Dept / School of Medicine.	
Country	Spain	Phone:
Keywords	Neurodegeneration, neuroinflammation, neurological disorders	

A.2. Previous Professional Experience

Period	Position / Institution
2021 - 2024	Associate Professor / UCM
2019 - 2021	Assistant Professor / UCM
2016 - 2019	Adjunct Professor / UCM
2012 - 2019	Ph.D. Researcher / CIBERNED
2012 - 2012	Ph.D. Researcher / CSIC
2010 - 2011	Researcher staff / CSIC
2008 - 2009	Researcher staff / CIBERNED
2007 - 2008	Researcher staff / CSIC
2006 - 2007	Researcher staff / CSIC
2002 - 2006	Predoctoral student / CSIC
2001 - 2002	Internal student / UCM

A.3. Education / Academic Background

Grade/Master/Tesis	University / Country	Año
PhD. in Neuroscience	Universidad Autónoma de Madrid / Spain	2011
Master in Biochemistry, Molecular Biology and Biomedicine	Universidad Autónoma de Madrid / Spain	2005
Bachelor of Science	Universidad Complutense de Madrid / Spain	2002

A.4. General Metrics of Scientific Output.

- internal undergraduate student: 1 year
- predoctoral period: 5 years
- principal investigator: 12 years
- research assistant: 4 years
- postdoctoral period: 8 years

Articles in journals:

- published: 66 (5% as corresponding author)
- submitted: 1 (as corresponding author)

Citations: 2.205 (Scopus)

Publications in the **first Quartile** (Q1): 89.2% (WoS)

Publications in the **first Decile** (D1): 68,1% (WoS)

H index: 32 (Scopus)

Patents: 5

R&D projects:

- **national:** 24 (5 of them as Principal Investigator)
- **international:** 1 (as Principal Investigator)

Works submitted to national/international conferences: 63

Experience in supervising doctoral thesis and other projects:

- Doctoral thesis supervisor: 2
- International Master Thesis (University of Amsterdam): 1
- End of Course projects supervisor: 11
- End of Master projects supervisor: 10.
- Technical superior degrees in pathological anatomy and cytology supervisor: 6

Teaching activity:

- Master in Neuropharmacology (UAM Medicine School): professor (currently)
- Master in Molecular Biomedicine (UAM Medicine School): professor (currently)
- Expert Degree in Public Communication and Science Dissemination (UAM): professor.
- Medicine Grade (UCM Medicine School): tenured professor (currently)
- Medicine Grade (UCM Medicine School): honorary collaborator (finalized)

International Comitees membership

- Expert Board Member of the European Research Executive Agency (European Commission)
- Expert Board Member of the European Innovation Council and SMEs Executive Agency (European Commission)
- Expert Board Member of the Spanish Service for the Internationalization of Education (SEPIE).

Awards and honours.

- I3 certificate of excellence in scientific production and technological activity. 2020. MICINN.
- Best scientific image award. 2020 and 2021. UCM-Scientific Communication Awards.
- Excellence in Education Prize. 2017-2018-2019–2020–2021-2022-2023. UCM Docentia Program.
- Best scientific image award. 2017. IBIDI Scientific Photo Contest.
- Ph.D. summa cum laude with a Special Doctorate Mention. 2012. UAM.

Scientific divulgation activities:

- Communicate and Disseminate Science (2019 and 2020). Organizer and Speaker.
- Ramón y Cajal Workshop. (2018-2019-2020). Organizer.
- Spanish Scientific Week (2018-2025). Organizer and Speaker.
- BBDiag ITN Marie Curie Meeting. Organizer.
- Spanish Scientific Week (2017-2025). Speaker.
- Workshop on Autophagy and Neurodegeneration (2017). Organizer.
- Celebrate Brain Awareness Week (2017-2025). Organizer and speaker.

Parte B. CURRICULUM SUMMARY

Jose A. Morales-García is a neuroscientist holding a **permanent position as Tenured Professor** at Complutense University of Madrid (UCM) and a **Research Partner** at the "12 de octubre" Hospital Research Institute, specializing in Neuroscience and Mental Health. For 10 years, he was a key member of the "Psychobiology of Addictions group" within the UCM-Scientific Research Network and currently leads his own UCM group, "Preclinical Models of Neurological Disorders."

Dr. Morales-García was awarded his Ph.D. *summa cum laude* in 2011 from Autonoma University of Madrid (UAM). His doctoral thesis, "Identification and analysis of new cellular targets implicated in neurogenesis and neurodegeneration," received a Special Doctorate Mention, recognizing his distinguished research achievement. His comprehensive pre-doctoral training, conducted across various national and international universities, including Würzburg University (Germany) through a COST action fellowship and Tübingen University (Germany) via a Marie Curie fellowship, centered on the *in vitro* and *in vivo* study of mechanisms underlying neurodegenerative diseases, primarily Parkinsonism, with the aim of developing innovative treatment compounds.

Dr. Morales-García's postdoctoral journey at the Spanish National Research Council (CSIC), first at the Institute for Biomedical Research "Alberto Sols" and subsequently at the Medicinal Chemistry Institute, further solidified his expertise in neurodegenerative diseases. During this period, he investigated the role of diverse cellular targets in neurogenesis, anti-inflammatory, and neuroprotective processes, all geared towards developing new therapeutic compounds. His prolific research career is evidenced by his participation in **25 national and international scientific projects**, **66 peer-reviewed scientific articles**, and **5 intellectual patents**. Over the past five years, he has successfully spearheaded **three significant projects**: a Spanish National Project (Proyectos Colaborativos CIBERNED. Ref. 2015/03), the Santander-UCM Project ("Lipofagia: una nueva aproximación terapéutica para el tratamiento de la enfermedad de Parkinson"), and a European Marie Curie-Innovative Training Network (Call: H2020-MSCA-ITN-2016. Proposal Number: 721281). He is **currently leading** the Spanish National Project "Melatonin: Analysis and validation in a preclinical model of mechlorethamine-induced neurological damage" and is actively involved in the ongoing projects: "Epidemiological and Immunoprotection Characterization in Populations with Alcohol Use Disorders" (Ministry of Health) and "Therapeutic Potential of Melatonin as an Adjuvant to Temozolomide: An Integrative Approach to Improve Treatment Response in Glioblastoma" (Community of Madrid)". His exceptional research contributions have been formally recognized with the **I3 certificate**, a prestigious award for outstanding scientific production and technological activity. He maintains extensive scientific collaborations with numerous national and international institutions, reflected in his publication record.

Beyond his research, Dr. Morales-García is deeply committed to nurturing the next generation of scientists. He has an impressive track record in **training new researchers**, having supervised 21 TFM/TFGs, 2 national theses, and 1 international master thesis. He is a frequent **reviewer for international scientific journals**, serves as an **Editor for the Frontiers Editorial Group**, and acts as an **Expert for the European Commission**. His dedication to education extends to his **teaching responsibilities** in the Degree of Medicine at the Medical School (UCM), the Master in Neuropharmacology at the Medical School (UAM), and the Expert Degree in Public Communication and Dissemination of Science at UAM. Furthermore, he actively engages in **scientific dissemination activities**, both as an organizer and speaker, and directs several educational innovation projects funded by the UCM.

Parte C. KEY ACHIEVEMENTS.

C.1. Publications in the last 5 years.

1. Discovery of (3-Phenylcarbamoyl-3,4-dihydro-2H-pyrrol-2-yl)phosphonates as Imidazoline I2 Receptor Ligands with Anti-Alzheimer and Analgesic Properties. Journal of Medicinal Chemistry, Vol. 68, Núm. 3, pp. 2551-2573.

2. Fermentable dietary fibers reduce voluntary alcohol intake and modulate gut microbiota composition in rats. Journal of Functional Foods, Vol. 134.

3. In Vivo Evidence of Melatonin's Protective Role in Alkylating-Agent-Induced Pulmonary Toxicity: A Systematic Review. Antioxidants, Vol. 14, Núm. 6.

4. Modeling neurodegeneration and neuroinflammation in Parkinson's Disease: Animal-based strategies Methods in Cell Biology, Vol. 197, pp. 81-114.
5. Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties. European Journal of Medicinal Chemistry, Vol. 277
6. Exploring the reactivity of bicyclic α-iminophosphonates to access new imidazoline I2 receptor ligands. Bioorganic Chemistry, Vol. 142.
7. C/EBPβ Regulates TFAM Expression, Mitochondrial Function and Autophagy in Cellular Models of Parkinson's Disease. International Journal of Molecular Sciences, Vol. 24, Núm. 2.
8. Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson's Disease. Cells, Vol. 12, Núm. 5.
9. Dissecting operant alcohol self-administration using saccharin-fading procedure. Neuropsychopharmacology Reports, Vol. 43, Núm. 1, pp. 12-22
10. Melatonin: A multitasking indoleamine to modulate hippocampal neurogenesis. Neural Regeneration Research, Vol. 18, Núm. 3, pp. 503-505
11. Neuroprotective properties of queen bee acid by autophagy induction. Cell Biology and Toxicology, Vol. 39, Núm. 3, pp. 751-770
12. Preclinical Evaluation of an Imidazole-Linked Heterocycle for Alzheimer's Disease. Pharmaceutics, Vol. 15, Núm. 10
13. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies Addiction biology, Vol. 27, Núm. 6, pp. e13229
14. Editorial: New Insights Into Adult Neurogenesis and Neurodegeneration: Challenges for Brain Repair. Frontiers in Neuroscience.
15. Insights into the Pharmacokinetics and In Vitro Cell-Based Studies of the Imidazoline I2 Receptor Ligand B06. International Journal of Molecular Sciences, Vol. 23, Núm. 10
16. Neuroprotective and Anti-Inflammatory Effects of Linoleic Acid in Models of Parkinson's Disease: The Implication of Lipid Droplets and Lipophagy. Cells, Vol. 11, Núm. 15
17. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Journal of Medicinal Chemistry, Vol. 65, pp. 4727- 4751.
18. Seroprevalence of anti-SARS-CoV-2 IgG antibodies: relationship with COVID-19 diagnosis, symptoms, smoking, and method of transmission. IJID Regions, Vol. 4, pp. 10-16
19. Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back. Ayahuasca Healing and Science, pp. 1-19.
20. The immune system through the lens of alcohol intake and gut microbiota. International Journal of Molecular Sciences, Vol. 22, Núm. 14
21. Martínez-Chacón G; Paredes-Barquero M; Yakhine-Diop SMS; etal; Niso-Santano M.2021. Neuroprotective properties of queen bee acid by autophagy induction.Cell Biol Toxicl. doi: 10.1007/s10565-.
22. The Immune System through the Lens of Alcohol Intake andGut Microbiota. International Journal of Molecular Science. 22-14, pp.7485.
19 Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. Aging (Albany NY). 12-17, pp.16690-16708.
20. N,N-dimethyltryptamine (DMT), compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. TranslationalPsychiatry. Grupo Nature. 10-1, pp.331.
21. Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson disease. Molecular Neurobiology. 57-2, pp.806-822.

C.3. Projects and Grants in the last 5 years.

1. Evaluation of the efficacy of melatonin as a therapeutic agent against mustard gas–induced toxicity. Ministry of Defense – Directorate General of Armament and Materiel. 2025-2029.
2. Therapeutic Potential of Melatonin as an Adjuvant to Temozolomide: An Integrative Approach to Improve Treatment Response in Glioblastoma. Com. de Madrid. 2025-2027
3. Analysis and validation of melatonin in a preclinical model of neurological damage induced by mechlorethamine exposure. IP. Spanish Ministry of Science, Innovation and Universities. 2023-2027.
4. Epidemiological and immunoprotection characterization in populations with alcohol use disorders. Ministry of Health. 2023-2025.
5. Lipophagy: a novel therapeutic approach for the treatment of Parkinson's disease. IP. Santander-UCM. 2022-2023.
6. Blood Biomarker-based Diagnostic Tools for Early-stage Alzheimer's Disease. Marie Curie ITN - European Union. IP. 2018-2020.